This is educational information, not medical advice, and The Peptide University does not sell peptides, supplies, or supplements. Many compounds discussed here are sold as “research chemicals” and are not approved for human use outside of clinical trials. Laws vary by country, and nothing here is a recommendation to obtain or use anything. Talk to a qualified clinician about your own situation.
Liraglutide is an FDA-approved GLP-1 receptor agonist, sold as Victoza (type 2 diabetes) and Saxenda (weight management). Unlike the weekly newer agents, it's a once-daily injection.
How it works
Same core mechanism as semaglutide — it mimics GLP-1 to blunt appetite, slow gastric emptying, and improve glucose handling. Its shorter action is why it's dosed daily.
The evidence
Liraglutide has a large trial base. In class comparisons it reported roughly 5% placebo-corrected weight loss — meaningful, but below semaglutide (~12%) and tirzepatide (~18%). It remains a well-characterized, approved option.
Safety
Predominantly gastrointestinal side effects, like the rest of the class, with the same less-common concerns (pancreatitis, gallbladder). See the GLP-1 side-effects article.
FAQ
QWhy choose a daily drug over weekly?
It's largely historical and clinical preference; the weekly agents generally show larger weight loss. That's a clinician conversation.
QIs it a peptide?
Yes — a GLP-1 analogue, chemically a peptide, and an approved, well-studied one.
Sources
This profile summarizes the following. Follow the links to read the originals — and remember that summaries age, so check for newer information.
- GLP-1 agonists for obesity: outcomes & risks (PMC)
- GI adverse events with GLP-1 RA: meta-analysis (Int. J. Obesity)
Inclusion here is not endorsement of any source's claims; several are cited so you can compare how different outlets characterize the same evidence.
Questions & comments
No account, no login — leave a name or stay anonymous. Ask a question, add something the article missed, or answer someone else. Be kind and cite sources where you can.